FCCC LOGO Faculty Publications
Perini GF , Pro B
Brentuximab Vedotin in CD30+ Lymphomas
Biol Ther. 2013 ;3 :15-23
PMID: 24392301    PMCID: PMC3873074   
Back to previous list
Abstract
Monoclonal antibodies (mAb) have become an effective treatment strategy for hematologic malignancies. CD30 is a rational target for therapy due to its limited expression on normal tissues and the strong and uniform expression on malignant cells in classical Hodgkin's lymphoma (cHL) and anaplastic large-cell lymphoma (ALCL). Brentuximab vedotin, an anti-CD30 antibody-drug conjugate, utilizes the targeting properties of mAb to deliver a cytotoxic agent inside the malignant cell. Brentuximab vedotin has significant clinical activity in patients with relapsed or refractory cHL and relapsed or refractory ALCL, and has the potential to represent a significant advance in modern oncology.
Notes
Perini, Guilherme Fleury Pro, Barbara REVIEW Biol Ther. 2013;3:15-23. Epub 2013 Mar 1.